SCHEMBL4114246

SCHEMBL4114246

O=C(O)c1cnn2c(-c3ccc(OC(F)(F)F)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
DHODH Q02127 2/20 0.39
NR3C1 P04150 1/20 0.38
FFAR4 Q5NUL3 2/20 0.38
FFAR1 O14842 1/20 0.38
CYP2C9 P11712 1/20 0.38
SCN5A Q14524 1/20 0.38
EIF4E P06730 2/20 0.38
EGLN1 Q9GZT9 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SERPINE1 P05121 1/20 0.38
KDM5A P29375 1/20 0.37
KDM2B Q8NHM5 1/20 0.37
KDM4C Q9H3R0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4124741 0.90 PDE2A (0.41) KDM4EALDH1A1NR3C1FFAR4FFAR1
SCHEMBL4115655 0.87 GPR119 (0.43) KDM4EALDH1A1EGLN1NPC1MAPT
SCHEMBL2083955 0.85 RAB9A (0.51) KDM4EALDH1A1DHODHEGLN1NPC1
SCHEMBL4113927 0.82 KDM4E (0.39) KDM4EALDH1A1EIF4EEGLN1NPC1
SCHEMBL4120187 0.82 TYK2 (0.40) ABL1TRPV1
SCHEMBL2086513 0.81 KDM4E (0.41) KDM4EALDH1A1DHODHNR3C1EGLN1
SCHEMBL2055528 0.79 GPR119 (0.42) KDM4EALDH1A1NR3C1MAPTRAB9A
SCHEMBL4127132 0.78 RAB9A (0.47) KDM4EALDH1A1DHODHNPC1MAPT
SCHEMBL4115065 0.77 RAB9A (0.52) KDM4EALDH1A1EGLN1NPC1MAPT
SCHEMBL4115056 0.77 GPR119 (0.41) KDM4EALDH1A1NR3C1MAPTTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD AKR1C2 685/4885AKR1C1 409/4885KDM4E 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.